Table 2: Results of randomized trials on immediate adjuvant RT.

TrialSWOG 8794EORTC 22911ARO 96-02

Overall survivalHR: 0.72
(95% CI 0.55–0.96),
HR: 1.09
(98% CI 0.67–1.79),
Not reported

bNEDHR: 0.43
(95% CI 0.31–0.58),
HR: 0.48
(98% CI 0.37–0.62),
HR: 0.53
(95% CI 0.37–0.79),

Metastasis-free survivalHR: 0.71
(95% CI 0.54–0.94),
Not reported98% versus 95.1 % (n.s.)

Clinical progression-free survivalHR: 0.62
(95% CI 0.46–0.82),
HR: 0.61
(98% CI 0.43–0.87),
Not reported

Time to initiation of hormonal therapyHR: 0.45
(95% CI 0.29–0.68),
Not reportedNot reported

Overall toxicity23.8% versus 11.9%,
4.2% versus 2.6%
(Grade 3; )
21.9% versus 3.7%,

Rectal toxicity3.3% versus 0%,
Not reported1.4% versus 0%

Urinary stricture17.8% versus 9.5%,
Not reportedNot reported

Total urinary incontinence6.5% versus 2.8%,
Not reportedNot reported

HR: hazard ratio; CI: confidence interval; n.s.: not significant.